Dec 06, 2019 / 09:30AM GMT
Olav Hellebø,ReNeuron Group plc-CEO&Director
Good morning, everyone. Welcome to ReNeuron's interim results presentation for the 6 months ending 30th of September 2019.
You will see some highlights throughout this presentation, first of all, strong financials. You will see some strict cash management. You will see GBP 21 million in cash. You will see an accelerated RP program. You will see an expanded stroke trial. And also in the period, we shouldn't forget the great partnering agreement we signed in April with Fosun for rights in China, and we're obviously working hard on the next deal. So those are the quick highlights.
Before we jump into the presentation, we'll start with the disclaimer. And I assume you read that now.
So ReNeuron, we are a leader in cell-based therapeutics. We're based, obviously, in the U.K., also have a site in Boston for our clinical team. Everything we do is allogeneic cell therapy. We have 2 clinical-stage programs with a number of validations and data coming over the next year and 2.
The
Half Year 2020 ReNeuron Group PLC Earnings Call Transcript
Dec 06, 2019
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers